Sherbrooke Park Advisers LLC Has $364,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Sherbrooke Park Advisers LLC raised its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 7.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,571 shares of the company’s stock after purchasing an additional 443 shares during the period. Sherbrooke Park Advisers LLC’s holdings in Tarsus Pharmaceuticals were worth $364,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. Paradigm Biocapital Advisors LP increased its stake in Tarsus Pharmaceuticals by 3.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,531,896 shares of the company’s stock valued at $140,191,000 after purchasing an additional 91,451 shares in the last quarter. Jennison Associates LLC increased its stake in Tarsus Pharmaceuticals by 14.8% in the fourth quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock valued at $138,432,000 after purchasing an additional 321,552 shares in the last quarter. Vanguard Group Inc. increased its stake in Tarsus Pharmaceuticals by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company’s stock valued at $117,117,000 after purchasing an additional 17,839 shares in the last quarter. Lord Abbett & CO. LLC increased its position in shares of Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock worth $70,873,000 after acquiring an additional 685,111 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Tarsus Pharmaceuticals by 36.7% during the fourth quarter. Invesco Ltd. now owns 932,115 shares of the company’s stock worth $51,611,000 after acquiring an additional 250,018 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

Insider Activity

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 8,534 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $427,638.74. Following the sale, the chief executive officer now directly owns 53,635 shares in the company, valued at $2,687,649.85. This represents a 13.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Bryan Wahl sold 3,084 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $154,539.24. Following the completion of the sale, the general counsel now owns 51,712 shares in the company, valued at $2,591,288.32. This represents a 5.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock valued at $1,581,173 in the last three months. Company insiders own 8.25% of the company’s stock.

Tarsus Pharmaceuticals Trading Up 0.5%

TARS opened at $43.70 on Monday. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.84 billion, a P/E ratio of -11.47 and a beta of 0.94. The company has a fifty day moving average price of $48.05 and a two-hundred day moving average price of $49.23.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $78.34 million during the quarter, compared to analysts’ expectations of $72.50 million. Analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Oppenheimer increased their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Jefferies Financial Group increased their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. HC Wainwright reissued a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Barclays reduced their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $66.33.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.